CanSino Biologics Gelecekteki Büyüme

Future kriter kontrolleri 5/6

CanSino Biologics kazanç ve gelirin sırasıyla yıllık 141.4% ve 33.3% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 123.9% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 5.4% olacağı tahmin edilmektedir.

Anahtar bilgiler

141.4%

Kazanç büyüme oranı

123.9%

EPS büyüme oranı

Biotechs kazanç büyümesi	42.5%
Gelir büyüme oranı	33.3%
Gelecekteki özkaynak getirisi	5.4%
Analist kapsamı	Low
Son güncelleme	02 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

CanSino Biologics Inc.'s (HKG:6185) Price Is Right But Growth Is Lacking After Shares Rocket 37%

Nov 11

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

Jun 20

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Apr 07

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Feb 06

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Oct 13

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Sep 07

Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts

Jul 13

Is CanSino Biologics (HKG:6185) Using Too Much Debt?

Jul 01

We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt

Mar 15

Kazanç ve Gelir Büyüme Tahminleri

SEHK:6185 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	1,659	136	332	592	4
12/31/2025	1,205	-50	-28	356	5
12/31/2024	896	-195	-136	105	2
9/30/2024	749	-720	-936	-447	N/A
6/30/2024	635	-867	-940	-385	N/A
3/31/2024	371	-1,513	-1,201	-671	N/A
12/31/2023	357	-1,483	-1,519	-908	N/A
9/30/2023	503	-1,420	-1,867	-1,207	N/A
6/30/2023	431	-1,763	-2,339	-1,375	N/A
3/31/2023	636	-1,170	-2,660	-1,599	N/A
12/31/2022	1,035	-909	-2,927	-1,852	N/A
9/30/2022	1,921	106	-1,733	-587	N/A
6/30/2022	2,868	989	-992	68	N/A
3/31/2022	4,332	2,050	328	1,464	N/A
12/31/2021	4,300	1,914	847	2,050	N/A
9/30/2021	3,105	1,113	18	1,065	N/A
6/30/2021	2,082	643	-250	531	N/A
3/31/2021	488	-388	-873	-317	N/A
12/31/2020	25	-397	-638	-350	N/A
9/30/2020	6	-239	-413	-230	N/A
6/30/2020	4	-189	-333	-196	N/A
3/31/2020	6	-135	-310	-164	N/A
12/31/2019	2	-157	-271	-154	N/A
9/30/2019	6	-137	-265	-131	N/A
6/30/2019	11	-156	-280	-140	N/A
3/31/2019	9	-158	-252	-132	N/A
12/31/2018	9	-138	-284	-124	N/A
12/31/2017	9	-64	N/A	-56	N/A
12/31/2016	8	-50	N/A	-34	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 6185 önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.3% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: 6185 önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: 6185 önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: 6185 şirketinin gelirinin (yıllık 33.3% ) Hong Kong pazarından (yıllık 7.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 6185 şirketinin gelirinin (yıllık 33.3% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 6185 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 5.4 %).

CanSino Biologics Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates fall by 10%

Consensus EPS estimates upgraded to CN¥1.19 loss

Consensus EPS estimates upgraded to CN¥1.04 loss, revenue downgraded

Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023

Consensus EPS estimates fall by 49%

CanSino Biologics Inc. Provides Earnings Guidance for the Period from January 1, 2022 to December 31, 2022

Recent updates

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Case for the Haemophilus Influenzae Type B Conjugate Vaccine, Freeze-Dried

CanSino Biologics Inc.'s (HKG:6185) Price Is Right But Growth Is Lacking After Shares Rocket 37%

New minor risk - Profitability

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

CanSino Biologics Inc. to Report Q3, 2024 Results on Oct 30, 2024

Co-Founder recently bought HK$436k worth of stock

High number of new directors

Co-Founder recently bought HK$367k worth of stock

Consensus EPS estimates fall by 10%

Co-Founder recently bought HK$186k worth of stock

Co-Founder recently bought HK$377k worth of stock

CanSino Biologics Inc. to Report First Half, 2024 Results on Aug 30, 2024

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

CanSino Biologics Inc., Annual General Meeting, Jun 27, 2024

CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee

Consensus EPS estimates upgraded to CN¥1.19 loss

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Cansino Biologics Inc. Announces Positive Preliminary Results from Phase I Clinical Trials of the Protein-Based Pneumococcal Vaccine

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Full year 2023 earnings: EPS and revenues miss analyst expectations

CanSino Biologics Inc. to Report Q1, 2024 Results on Apr 30, 2024

Consensus EPS estimates upgraded to CN¥1.04 loss, revenue downgraded

Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine

Full year 2023 earnings: EPS and revenues miss analyst expectations

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023

CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine

Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Enrollment for TDCP Adolescent and Adult

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case

Third quarter 2023 earnings released

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Second quarter 2023 earnings released: CN¥2.82 loss per share (vs CN¥0.44 loss in 2Q 2022)

New minor risk - Share price stability

CanSino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc. Announces CS-2032 Zoster Vaccine Obtains Clinical Trial Approval from Canada

CanSino Biologics Inc. to Report First Half, 2023 Results on Aug 22, 2023

Cansino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc., Annual General Meeting, Jun 30, 2023

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Full year 2022 earnings released: CN¥3.65 loss per share (vs CN¥7.74 profit in FY 2021)

Consensus EPS estimates fall by 49%

CanSino Biologics Inc. Provides Earnings Guidance for the Period from January 1, 2022 to December 31, 2022

Non-Executive Director recently sold HK$3.4m worth of stock

Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?

Cansino Biologics Inc. Announces Covid-19 Mrna Vaccine Cs-2034 Achieved Positive Interim Data in A Clinical Trial Evaluating the Safety and Immunogenicity of the Heterologous Cs-2034 Booster

CanSino Biologics Inc. Announces Clinical Research Results of A Clinical Trial of Bivalent Recombinant Covid-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation in Adults Aged 18 Years and Above

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

Less than half of directors are independent

CanSino Biologics Inc.'s Recombinant Covid-19 Vaccine (Adenovirus Type 5Vector) for Inhalation Approved for Emergency Use in Morocco

Consensus EPS estimates fall by 73%

Consensus revenue estimates fall by 12%

Now 38% undervalued

Third quarter 2022 earnings released

Investor sentiment improved over the past week

CanSino Biologics Inc. to Report Q3, 2022 Results on Oct 28, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up

CanSino Biologics Inc. Recombinant Covid-19 Vaccine for Inhalation Included for Emergency Use as A Booster Vaccine in PRC

Consensus revenue estimates fall by 41%

Investor sentiment deteriorated over the past week

Things Look Grim For CanSino Biologics Inc. (HKG:6185) After Today's Downgrade

Should You Be Adding CanSino Biologics (HKG:6185) To Your Watchlist Today?